卓正医疗火爆认购超1117倍！健康服务消费赛道稀缺黑马上市在即

Group 1 - The core viewpoint of the article highlights the strong market response to 卓正医疗's public offering, with a subscription amount reaching 35.3 billion HKD and an oversubscription rate of approximately 1117.92 times [1] - The company plans to issue 4.75 million shares globally, with a price range between 57.7 HKD and 66.6 HKD, aiming to raise up to 320 million HKD [1] - 卓正医疗 is positioned in a popular health service sector, supported by notable investors such as Tencent and H Capital, which enhances its market credibility and potential for stock price appreciation post-listing [1] Group 2 - The company has demonstrated significant revenue and profit growth, with revenue increasing from 470 million CNY in 2022 to 960 million CNY in 2024, reflecting a compound annual growth rate (CAGR) of 42.2% [2] - Gross profit surged from 43.98 million CNY to 230 million CNY during the same period, with a CAGR of 126.7%, indicating that profit growth outpaces revenue growth [2] - The company achieved profitability in 2024, with adjusted net profit reaching 10.45 million CNY in the first eight months of 2025, alongside positive cash flow from operations over the past three years [2] Group 3 - 卓正医疗 employs a "family doctor" membership model, providing a comprehensive range of medical services that enhances customer loyalty, with an average of nearly four visits per customer annually [3] - The company has a low customer acquisition cost, with marketing expenses constituting only 2.7%, 1.2%, and 1.7% of revenue from 2022 to 2024, significantly lower than the industry average of 10%-40% [3] - Over 85% of the company's revenue comes from cash payments, indicating low reliance on government insurance, which provides resilience against policy fluctuations [3] Group 4 - The company's operations are concentrated in major cities with strong consumer spending, having established 19 medical service institutions across 10 cities, including Shenzhen, Beijing, and Shanghai, and expanded to overseas markets like Singapore and Malaysia [4] - 卓正医疗's business model has been validated by achieving profitability in 2024 and continued positive operating profits in 2025, supported by stable cash flow from its membership system [4] Group 5 - As the industry shifts towards high-quality growth, 卓正医疗, with its solid specialized capabilities and strong brand effect, is expected to capture more market share [5] - The company's unique positioning in both its sector and business model is likely to continue attracting market investment [5]